Skip to Main Content

Good morning, everyone, and welcome to the middle of the week. Hard to believe we arrived here so quickly, yes? Well, this means only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Remember that no prescription is required, which means there is no rebate involved. How about that? Meanwhile, here are a few items of interest. Hope you have a smashing day and, as always, keep us in mind when you run across anything fascinating. …

Allergan (AGN) shareholders rejected a proposal to order the immediate split of the chairman and chief executive roles, with 61.3% of shareholders backing Brent Saunders, who holds both jobs, Reuters reports. The Appaloosa hedge fund, run by billionaire investor David Tepper, made the proposal, arguing Allergan has a questionable business strategy and excessive executive pay. Allergan is under pressure to rescue its falling stock price and agreed in March to split the chairman and CEO roles, but only at its next leadership change. Saunders, 49, has no plans to step down.


Progressive lawmakers in the Democratic Party are increasingly warning that they would forcefully oppose any effort to set up a system of arbitration to help lower drug prices, a model that would fall short of their demands to allow the federal government to negotiate with makers, STAT writes. The idea has implicit backing of House Speaker Nancy Pelosi (D-Calif.), whose top health policy aide has been focused on the proposal in talks with other experts. Her support could put the idea on the fast track for congressional action, though no bill on the issue has yet been introduced in Congress.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.